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Abstract
Purpose of Review Diabetic ketoacidosis (DKA) and hyper-
glycemic hyperosmolar state (HHS) are diabetic emergencies
that cause high morbidity and mortality. Their treatment dif-
fers in the UK and USA. This review delineates the differ-
ences in diagnosis and treatment between the two countries.
Recent Findings Large-scale studies to determine optimal man-
agement of DKA and HHS are lacking. The diagnosis of DKA
is based on disease severity in the USA, which differs from the
UK. The diagnosis of HHS in the USA is based on total rather
than effective osmolality. Unlike the USA, the UK has separate
guidelines for DKA andHHS. Treatment of DKA andHHS also
differs with respect to timing of fluid and insulin initiation.
Summary There is considerable overlap but important differ-
ences between the UK and USA guidelines for the manage-
ment of DKA and HHS. Further research needs to be done to
delineate a unifying diagnostic and treatment protocol.
Keywords Diabetic ketoacidosis .Management . Survey .
Hyperglycemic hyperosmolar state
Introduction
Diabetic ketoacidosis (DKA) and hyperglycemic
hyperosmolar state (HHS) are hyperglycemic emergencies
that continue to account for increased burden of hospitaliza-
tions in both the USA [1] and UK [2]. Historically, both DKA
and HHS were initially described as one entity but subse-
quently recognized as separate conditions. Since the advent
of insulin, mortality has fallen for DKA and HHS, but the risk
remains high. Previous work from the UK and seminal ran-
domized controlled studies performed in the USA by Abbas
Kitabchi form the basis of treatment of DKA and HHS.
However, only a few of these were randomized studies to
guide clinicians on the best way to manage DKA and HHS.
Whilst the principles are well known—fluids, insulin, and
electrolytes, the questions remain about how much, how fast,
etc. This lack of a firm evidence base has led to these small
differences in management in both the USA and UK.
Additional factors, such as the healthcare environment, also
have an impact. In this article, we will discuss the main dif-
ferences between the USA and UK in the treatment of DKA
and HHS.
Diabetic Ketoacidosis
Prior to the discovery and isolation of insulin in 1922 by
Banting and Best, type 1 diabetes was universally fatal within
a few months of initial diagnosis. Once mass production was
started, the challenge to those early pioneers of insulin treat-
ment was learning how to use this newwonder drug, e.g., how
much to give and how often to give it, in order to treat the
hyperglycemia without raising the inherent risk of
hypoglycemia.
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In 1945, Howard Root in Boston described how they had
improved the outcomes for people with diabetic ketoacidosis
(DKA), reducing mortality to 12% by 1940 and to 1.6% by
1945 using high doses of insulin—giving an average of
83 units within the first 3 h of treatment in 1940 and 216 units
by 1945 [3]. They described how in 1945, they used an aver-
age of 287 units in the first 24 h, but this ranged from 50 to
1770 units [3]. In Birmingham, UK, high-dose insulin was
also being used with similar success—doses varying depend-
ing on the degree of consciousness, with those unarousable on
admission given doses between 500 and 1400 units per 24 h
[4]. DKA remains a medical emergency; over time, mortality
has continued to fall but remains a significant risk, especially
amongst the young, socially isolated and when care provision
is fragmented [5•, 6•]. Overall, the diagnosis and treatment of
DKA are very similar in the UK and USAwith a few differ-
ences. The UK has separate guidelines on the management of
DKA [7], while the USA has a position statement on DKA
and HHS that was updated in 2009 [8]. The UK guideline
differs in several ways from the US position statement.
The concept of low-dose intravenous insulin was
established in the late 1960s and early 1970s by teams on
both sides of the Atlantic. The UK championed the use of
insulin infusions of between 1.2 and 9.6 units per hour at a
fixed rate [9–11]. In the USA, Kitabchi et al. used a variety
of low-dose insulin regimens, e.g., 0.22 units per kilogram
(with a subsequent sliding scale dependent on subsequent
glucose concentrations) or 0.33 units per kilogram followed
by an infusion of 7 units per hour [12, 13]. These regimens
led to a steady reduction in glucose and ketone concentra-
tions at a rate comparable to the higher insulin doses [9–11].
This then led the way to weight-based, fixed-rate intrave-
nous infusion rates [7, 14]. Kitabchi and colleagues went on
to do some seminal work looking at the effects of electrolyte
disturbances, including the effects of bicarbonate use in
DKA. Their significant contributions to the field have been
highlighted elsewhere [15].
There are few randomized studies to guide clinicians on
the best way to manage DKA. Whilst the principles are well
known—fluids, insulin, and electrolytes, the questions re-
main about how much, how fast, etc. This lack of a firm
evidence base has led to these small differences in manage-
ment. Additional factors, such as the healthcare environ-
ment, also have an impact. In the UK, there is the principle
of universal health coverage, where payment for healthcare
is deducted from income tax and care is provided free at the
point of delivery. In the USA, a predominantly insurance-
based system exists. In those who have no insurance or
minimal health insurance coverage, it would be important
to consider ways or providing safe and appropriate treat-
ment that is affordable for the patient and the caregivers.
This comparison between the two ways of treating DKA is
the focus of this article.
Differences in Diagnosis
Unlike the USA, the UK has separate guidelines on the man-
agement of DKA and HHS [16, 17]. These differ in several
ways from the US position statement on hyperglycemic emer-
gencies in adults authored by Kitabchi et al. that was last
updated in 2009 [8].
DKA—Diagnosis
There are differences in the diagnostic criteria for DKA be-
tween the UK and the USA (Table 1). There are several po-
tential implications of these differences. The UK criteria sug-
gest that you either have DKA or you do not. But, both doc-
uments state that the diagnosis can only be made when all
three criteria (the “D,” the “K,” and the “A”) are present.
The cornerstone of treatment is administration of fluids and
insulin with the endpoint of decreasing ketogenesis.
The UK Perspective
The UK guideline states that to make a diagnosis of DKA, a
prior history of diabetes, regardless of glucose concentrations,
although (a glucose >11 mmol/L (200 mg/dL) is specified), is
sufficient diagnostic criteria. Due to the availability of testing
of 3-beta-hydroxybutyrate testing at the bedside, measure-
ment of serum ketones with a level >3 mmol/L has been sug-
gested as part of the diagnostic criteria for ketoacidosis as
opposed to using the urine ketones. Also, the UK guidelines
state that using venous blood gas rather than arterial blood gas
with a pH <7.3 should be used for diagnosis of acidosis.
There are several advantages to the UK criteria.
Approximately 10% of patients with DKA present with
euglycemic DKA [18] or with glucose levels below the
thresholds set by the US guidelines. This is a condition that
is becoming more of an issue with the recognition that it can
occur in people taking sodium glucose co-transporter 2 inhib-
itors [19•] and in pregnancy [20]. Therefore, the emphasis on
the history of previous diabetes with a lower glucose threshold
than the US criteria allows for detection of euglycemic
ketoacidosis. The use of serum rather than urine ketones is
advantageous. People with DKA are usually dehydrated, and
thus, urine output is low; it may be several hours before urine
is produced, further delaying the instigation of appropriate
management. Any estimation of urine ketones collected in this
way will be an average of the concentration within the urine
held in the bladder since the last void. Finally, as the DKA
resolves, β-hydroxybutyrate is converted to acetoacetate,
which is then excreted into the urine, giving the (false) im-
pression that the condition is taking longer to resolve that it
actually is. For these reasons, urine ketone testing is not rou-
tinely recommended in the UK guideline. However, because
point-of-care, bedside blood ketone meters are not universally
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available in all hospitals at all times, there is provision made to
allow for the occasional use of urine ketones [16, 21••]. The
use of venous pH is recommended for the diagnosis of acido-
sis, because of the data suggesting that the differences be-
tween arterial and venous pH are not large enough to change
clinical management decisions [22–25]. Furthermore, the an-
ion gap is not used as part of the diagnosis of DKA in the UK.
This is in part because a serum chloride is neither routinely
reported as part of the blood gas analysis, nor reports of elec-
trolyte concentrations. In addition, the use of 0.9% sodium
chloride solution can cause a hyperchloremic metabolic aci-
dosis, and the persistent rise in serum chloride can give the
impression to those who are unwary or inexperienced that the
resulting high anion gap could be due to the persistent pres-
ence of ketones, rather than being due to the fluid
resuscitation.
The US Perspective
The US guidelines suggest using a glucose threshold of
>250 mg/dL (13.9 mmol/L), presence of positive serum and
urine ketones with an anion gap, and arterial pH <7.3 to make
the diagnosis of DKA. The biggest difference between the UK
and the US guideline is the classification of the severity of
DKA (Table 1). There are several advantages to categorizing
DKA according to severity.
The American Diabetes Association (ADA) consensus
guidelines recommend assessment of severity of DKA based
on mental status along with the laboratory parameters. While
the ADA guidelines acknowledge that approximately 10% of
patients with DKA present with lower glucose levels, they
emphasize that the key diagnostic feature of DKA is elevated
ketonemia. The reasons for dividing DKA presentation into
different levels of severity are multifactorial. One of the rea-
sons is due to availability of resources. In the UK, there is the
principle of universal health coverage, where payment for
healthcare is deducted from income tax and care is provided
free at the point of delivery. In the USA, a predominantly
insurance-based system exists. In those who have no or min-
imal health insurance coverage, it would be important to con-
sider ways or providing safe and appropriate treatment that is
affordable for the patient and the caregivers. The ADA guide-
lines also suggest that mental status be used to grade severity.
This particular emphasis allows for safer triage of patients
presenting to the emergency room to either the intensive care
units or step-down units. Further, as per the US guidelines,
patients with a bicarbonate level of 18 mmol/L can have mild
DKA. This is included to recognize that DKAmay be partially
treated prior to presentation at the hospital. It should be noted
that patients with DKA can have a wide range of acid-base
disorders and may have a small anion gap despite increased
beta-hydroxybutyrate concentrations [26]. This subset of pa-
tients may be erroneously classified as having mild DKA if
one was to look for just the anion gap.
For the diagnosis of ketoacidosis, the ADA 2009 guide-
lines recommend that measurement of ketones by nitroprus-
side reaction be used because it was more readily available.
However, since beta-hydroxybutyrate is the main product of
ketogenesis and the nitroprusside reaction does not measure
beta-hydroxybutyrate [27], the ADA guidelines suggest mea-
surement of beta-hydroxybutyrate if possible. Further, in the
US guidelines, anion gap is used in the diagnostic criteria.
Aggressive administration of insulin can cause hyperchloremia
and decrease the gap prior to an increase in bicarbonate.
Therefore, attention has to be paid to bicarbonate concentra-
tions rather than just the anion gap. The ADA guidelines also
recommend the use of arterial pH but state that venous pH can
also be used [25, 28, 29].
Treatment
Both documents agree that the primary treatment should
be fluid replacement and that the initial fluid replacement
of choice is 0.9% sodium chloride solution. The rates of
Table 1 UK vs USA diagnostic criteria for DKA
UK USA
Mild Moderate Severe
“D”—a glucose
concentration
>11.0 mmol/L (200 mg/dL)
or a previous history of
diabetes mellitus
>13.9 mmol/L
(>250 mg/dL)
>13.9 mmol/L
(>250 mg/dL)
>13.9 mmol/L
(>250 mg/dL)
“K”—the presence
of ketones
>3.0 mmol/L or significant
(>2+) on standard urine
ketone sticks
Urine or serum
ketone positive
Urine or serum
ketone positive
Urine or serum
ketone positive
“A”—confirmation
of an acidosis
pH <7.3 7.25 to 7.30 7.00 to <7.24 <7.00
Serum bicarbonate
(mmol/L)
<15 15 to 18 10 to <15 <10
Anion gap Not applicable >10 >12 >12
Adapted from [7, 8]
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fluid replacement are similar—the US document advocat-
ing 15–20 mL/kg/h (1–1.5 L) in the first hour (regardless
of severity) and the UK document 1 L in each of the first
2 h. Both documents agree that phosphate replacement is
not needed as the randomized controlled study by
Kitabchi et al. did not show differences in outcomes
[30]. The rate of insulin infusion is the same in both
documents at 0.1 units/kg/h. There are differences in
how the insulin infusion rate should be adjusted. The
guidelines differ as to the amount and timing of insulin
and the use of bicarbonate.
UK Perspective
The UK guideline recommends adjustment of insulin infu-
sion depending on the rate of fall of glucose (3.0 mmol/h
[54 mg/dL]) and serum ketones (0.5 mmol/h) with a corre-
sponding rise in bicarbonate concentration of 3.0 mmol/L.
The UK guideline also incorporates the new evidence to
show that the continued use of long-acting basal insulin
helps to prevent the rebound hyperglycemia seen when the
intravenous insulin is stopped [31].
US Perspective
The grading of the severity of DKA directly translates to the
relevant treatment regimen. In the USA, Kitabchi et al. per-
formed pioneering studies in the use of low-dose insulin reg-
imens for the treatment of DKA, e.g., 0.22 units per kilogram
(with a subsequent sliding scale dependent on subsequent glu-
cose concentrations) or 0.33 units per kilogram followed by an
infusion of 7 units per hour [12, 13]. A later study by
Umpierrez et al. also showed that frequent subcutaneous in-
sulin injections are just as efficacious as intravenous insulin
for the treatment of mild–moderate DKA [32]. Subcutaneous
insulin injections can more easily be performed in the general
medical units rather than the ICU.
For fluid management, the US guideline suggests the
use of 0.45% saline infusion depending on sodium levels.
The rate of adjustment of IV insulin differs as well. The
US guideline advocates increasing the infusion rate after
an hour if the glucose values do not fall by 10%. The UK
document does not recommend the use of bicarbonate
replacement with the rationale that fluid and insulin re-
placement alone will be sufficient to raise pH. The US
guideline says that bicarbonate should be given when
the pH is <6.9 until the pH is >7.0. Even though a pro-
spective randomized study did not show benefit for the
use of bicarbonate in severe DKA [33], bicarbonate ther-
apy is recommended when the pH is <6.9 because being
acidotic may cause adverse cardiovascular and pulmonary
effects [34].
Hyperglycemic Hyperosmolar State
Unlike DKA, the criteria for diagnosis of hyperglycemic
hyperosmolar state (HHS) are not as well defined. It was ini-
tially described as a separate entity causing diabetic coma by
Dreschfield [35] and Von Frerichs [36]. In the Bradshawe
lecture delivered by Dreschfield in 1886, he described three
types of diabetic coma. The first one that he described is a
gradual coma in older adults (age >40) and in overweight
adults without the characteristic acetone breath or acetone in
the urine. After this case, several authors described diabetic
coma in which polydipsia and polyuria were accompanied by
hyperglycemia but without the characteristic Kussmaul
breathing seen in DKA [37–39]. Unlike patients with DKA,
there was not a presence of ketones or beta-hydroxybutyrate.
The full extent of the metabolic derangements seen with HHS
was not fully described till the 1950s [40, 41]. In these papers,
the authors reported the severe hyperglycemia accompanied
by osmotic diuresis but without ketonuria. They also sug-
gested measurement of electrolytes such as sodium and chlo-
ride. After this, Gerich et al. [42] and Arieff and Carroll [43]
described HHS further and coined the term hyperglycemic
hyperosmolar nonketotic coma (HHNK or HONK). A com-
prehensive history of HHS was described in full detail in a
review by Pasquel and Umpierrez [44].
Diagnosis
HHS occurs mostly in adults and elderly patients and has a
higher mortality than DKA with death occurring in 5–16%
[45, 46]. The evolution of HHS is over several days to weeks,
and the most common presentation is altered mental status
[47, 48]. The UK has separate guidelines for the diagnosis
of HHS [17]. Due to the lack of randomized controlled trials
for the treatment of HHS, the ADA consensus has combined
both DKA and HHS [8]. Both statements recommend the
assessment of severity at presentation. However, the UK
guidelines give specific data cut points to determine the sever-
ity of HHS (Table 2). Both recommend evaluation of precip-
itating causes.
The unique distinguishing factor in HHS is the absence of
ketones or a low ketone production despite an insulinopenic
state. In general, glucose levels in HHS are higher than the
ones for DKA. Both the UK guidelines and the ADA suggest
similar glucose levels to diagnose HHS. The UK guidelines
suggest a cutoff value of glucose >30 mmol/L (540 mg/dL),
and the ADA consensus statement suggests a cutoff
>33.3 mmol/L (600 mg/dL). In addition to hyperglycemia,
patients with HHS present with severe dehydration due to
the chronic nature of hyperglycemia. Although there are a
subset of patients that present with both DKA and HHS, both
groups suggest making a diagnosis of HHS when the pH is
greater than 7.3 and the bicarbonate level is greater than
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15 mmol/L (UK guidelines) and >20 mmol/L for ADA con-
sensus statement along with minimal ketonemia. The differ-
ences in the diagnosis, althoughminimal, lie in the calculation
of osmolality and assessment of severity. The differences are
outlined in Table 2.
UK Perspective
Both the US and UK guidelines use the cutoff of
320 mOsm/kg for the diagnosis of serum osmolality.
This value is based on studies that show that mental status
changes occur with serum osmolality >320 mOsm/kg.
Osmolality is calculated by the formula [2 × measured
Na (meQ/L) + glucose (mg/dL)/18 + blood urea nitrogen
(mg/dL)]/2.8] or [2 × measured Na (mmol/L) + glucose
(mmol/L) + [urea (mmol/L)]. Blood urea nitrogen is not
an effective osmolyte as it can cross membranes without
an osmotic effect. The UK guidelines suggest several
ways of calculating serum osmolality, which do not in-
clude blood urea nitrogen levels. However, due to provid-
er attitudes, it is suggested that it is included in the
calculation.
US Perspective
Because of its ability to pass freely across plasma mem-
branes, the ADA guidelines recommend calculation of se-
rum osmolality without the inclusion of blood urea nitro-
gen. Therefore, the patients diagnosed with HHS as per
ADA consensus are likely to be more dehydrated prior to
receiving intervention for HHS. Again, whether this results
in different outcomes compared to the UK guidelines is
unclear.
Treatment
The treatment of HHS, as with DKA, involves correction
of dehydration and lowering glucose. Both guidelines rec-
ommend careful monitoring of serum osmolality in order to
avoid complications of rapid overcorrection. Both guide-
lines recommend initiation of IV fluids with approximately
1 l of 0.9% saline and aggressive correction of dehydration
till osmolality stops declining. Both guidelines suggest
maintaining glucose concentrations of 13.9–16.7 mmol/L
(250–300 mg/dL in the USA) and 10–15 mmol/L (180–
270 mg/dL in the UK). Patients with HHS have depleted
potassium stores although less than that in DKA. Both the
UK and the ADA consensus statements suggest giving po-
tassium if the concentration is less than 3.3 meQ/L
(3.3 mmol/L) and to not replace potassium if the concen-
tration is greater than 5.5 meQ/L (5.5 mmol/L) [8, 17].
The differences in the guidelines are with choice of fluid
with respect to sodium concentrations and timing of insulin
initiation.
UK Perspective
The UK guidelines recommend initial treatment with 1 l of
0.9% saline for the first hour with subsequent adjustment of
rate and fluids depending on changes in osmolality (3–8
mOsmol/kg/h) after the first hour for 6 h after presentation
with a decrease in glucose of 5 mmol/L/h (90 mg/dL/h).
The use of 0.45% saline is not routinely recommended.
However, the guidelines do make an exception for the
use of 0.45% saline when osmolality does not decline de-
spite adequate fluid administration. Intravenous insulin
should be started at weight-based, fixed-rate intravenous
insulin at 0.05 U/kg/h once glucose concentrations stop
declining with fluid resuscitation when glucose concentra-
tions stop declining with fluid resuscitation.
US Perspective
The ADA guidelines recommend initial treatment with 1–
1.5 L of 0.9% saline. Unlike the UK, they recommend
that 0.45% saline be administered when sodium levels
are elevated. Recommendations are made to change fluids
according to osmolality. In general, the recommendation is
to start intravenous insulin dose at 0.1 U/kg/h once osmo-
lality stops declining. They also suggest doubling the in-
sulin dose if glucose is not falling by 2.8–3.9 mmol/L/h
(50–70 mg/dL/h). Once glucose concentrations of 13.9–
16.7 mmol/L (250–300 mg/dL) are achieved, the ADA
Table 2 UK vs USA diagnostic criteria for HHS
UK USA
Hyperglycemia >30 mmol/L
(540 mg/dL)
>33.3 mmol/L
(600 mg/dL)
Hyperosmolarity >320 mOsm/kg >320 mOsm/kg
Calculation 2 × Na
(mmol/L) +
glucose
(mmol/L) +
urea (mmol/L)
2 × Na
(meQ/L) +
glucose
(mg/dL)/18 +
blood urea
nitrogen
(mg/dL)]/2.8
Lack of acidosis Ketones Low Low
pH >7.3 >7.3
Bicarbonate >15 mmol/L >20 mmol/L
Mental status
changes
Present Present
Adapted from [7, 8]
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guidelines recommend decreasing insulin dose to 0.02–
0.05 U/kg/h.
Conclusions
In summary, with respect to the management of DKA and
HHS, there are wide areas of overlap between the US and
UK guidelines. However, there are also equally wide areas
where opinions diverge. It is these areas where there are dif-
ferences of opinion that illustrate the lack of good research to
help guide the best treatments for patients. Ultimately, it is
fluid, insulin, and potassium replacements, but the questions
remain: how much and how fast? For example, there remain
questions on which fluid should be used [49] and whether the
use of bicarbonate alters the outcomes in those with low pH.
Furthermore, more work needs to be done to assess how DKA
is diagnosed. In the UK and elsewhere, chloride measure-
ments are not readily available, and therefore, it is impossible
to calculate the anion gap. Therefore, if an anion gap cannot be
calculated, how do institutions grade severity? Is severity
therefore incorrectly based on the presence of 1 or 2 of the
D, the K, and the A? If that is the case, then this puts the
classification of DKA at risk, and any research using DKA
needs to ensure standardization of diagnosis and assessment
of severity. Further areas of research also include prospective
trial of whether different severities of DKA require different
treatments and whether this affects outcomes. There are also
no prospective trials for the treatment of HHS. Data is also
lacking as to the physiologic basis and outcomes of patients
that present with combined DKA and HHS. Finally, both
guidelines need to be updated on the recognition and treat-
ment of euglycemic DKA.
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